Travere Awaits FDA FILSPARI Ruling As Valuation Gap Draws Attention [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Travere Therapeutics is awaiting an FDA decision on a label expansion for FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease. The upcoming ruling concerns a supplemental approval that could broaden FILSPARI's use beyond its current indication. The outcome may influence Travere's rare disease portfolio and treatment options for patients with limited therapies. Travere Therapeutics, traded as NasdaqGM:TVTX, is approaching this regulatory event with its shares at $31.42. The stock has returned 14.0% over the past week and 6.4% over the past month, while the 1 year return is 75.1%. Over a 3 year period, the stock shows a 50.8% return and over 5 years a 25.1% return, alongside a year to date return of a 20.5% decline. For investors, the FDA's decision on FILSPARI could shape expectations around Travere's rare kidney disease franchise and future revenue mix. It is a moment
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]Yahoo! Finance
- A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]Yahoo! Finance
- Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (TVTX) was upgraded by Piper Sandler from "neutral" to "overweight". They now have a $49.00 price target on the stock.MarketBeat
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- TVTX's page on the SEC website